|  |  |  |   | 
| 2-RWD | A Hierarchical Algorithm to Identify Pregnancy Start and Duration Using Structured EHR Data | Sunny Guin |  Received | 
|  | |||
| 2-IC | Evaluating the cost of telemonitoring in cardiology from a service provider´s perspective: a case study from Northern Italy | Paolo Candio |  Received | 
|  | |||
| 2-PCR | A Collection Of Essays on Patient Centricity in Intervention Development | Matthew Reaney |  Received | 
|  | |||
| 3-CO | A Systematic Literature Review and Network Meta-Analysis of Once-weekly Icosema With Daily Fixeddose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment | Lauren Rengger |  Received | 
|  | |||
| 4-HSD | Advancing Real-World Evidence in Diffuse Large B-cell Lymphoma: Insights From EHR-Derived Data in the UK | Darren Johnson |  Received | 
|  | |||
| 4-EE | A Budget Impact Model of Switching From Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring for Individuals With Type 2 Diabetes Mellitus Receiving Basal Insulin in Italy | Jessica Matuoka |  Received | 
|  | |||
| 4-MSR | A Layered Approach to Reducing Hallucinations in LLMs for Structured and Unstructured Clinical Data | Ashwin Rai |  Received | 
|  | |||
| 5-HSD | AI-Enabled Extraction of eGFR and BRAF Testing Patterns in Advanced NSCLC: IMPACT-NSCLC, a Multicentre Real-World Study (2019-2024) | Thibaut Vergnol |  Received | 
|  | |||
| 5-RWD | A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Haemophilia Patients in Spain | Sheena Thakkar |  Received | 
|  | |||
| 5-HPR | A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies | Viviana Hernandez |  Received | 
|  | |||
| 5-SA | A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia | Isabelle Lundqvist |  Received | 
|  | |||
| 6-PCR | A Methodological Review of WOMAC to EQ-5D Mapping Algorithms in Knee Osteoarthritis | Ines Guerra |  Received | 
|  | |||
| 6-MSR | A Multistate Framework for Analyzing Outcomes in Diffuse Large B-cell Lymphoma With Autologous Hematopoietic Stem Cell Transplant | Colleen Dumont |  Received | 
|  | |||
| 7-EPH | A Real-World Survey of Health Inequalities As Drivers for Burden on Male Hemophilia Patients in the US, EU5, and Asia | Sheena Thakkar |  Received | 
|  | |||
| 7-PT | The Association Between Average Sales Price Decline and Shortages in Small Molecule Injectable Oncology Therapies With Generic Competition | Joshua Roth |  Received | 
|  | |||
| 8-HTA | A Long and Winding Road: An Evaluation of NICE HST Appraisals Taking Longer Than Two Years for Guidance Publication | Bersabhe Solomon |  Received | 
|  | |||
| 9-EE | A Cost-Effectiveness Analysis of Abrocitinib Versus Upadacitinib and Baricitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis | Gulraj Matharu |  Received | 
|  | |||
| 9-RWD | Advanced Therapies and the Unmet Need in Systemic Lupus Erythematosus Patients Results From a Real-World Study in the United States and Germany | Victoria Barton |  Received | 
|  | |||
| 10-CO | Analysis of Pooled Real-World Utilization and Outcomes Data of rVIII-SingleChain Compared With Standard and Extended Half-Life FVIII Products for Prophylaxis of Haemophilia A in France, Germany, and Italy | Korinna Karampampa |  Received | 
|  | |||
| 10-MSR | A Two-Stage Bayesian Approach for Real-World Cost-Effectiveness Analysis: Combining Inverse Probability Weighting With Gamma-Beta Regression Model | Gian Luca Di Tanna |  Received | 
|  | |||
| 11-PCR | A Systematic Review of Trends From Migraine Preference Studies | Natasha Ramachandran |  Received | 
|  | |||
| 11-MT | Cost Analysis of the Extravascular Implantable Cardioverter-Defibrillator Compared to the Subcutaneous System in Patients at Risk of Sudden Cardiac Death in Italy | FRANCESCA MARIANI |  Received | 
|  | |||
| 12-CO | APDS Treatment in Germany: Decision Criteria, Costs, and Contribution of Leniolisib to Outcomes | Kirsten Herrmann |  Received | 
|  | |||
| 13-RWD | AI for Precision Oncology Evidence: Case Study Research From British Columbia, Canada | Deirdre Weymann |  Received | 
|  | |||
| 13-HTA | A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal | Alasdair Henry |  Received | 
|  | |||
| 14-EPH | Analysis of a Cancer Profile of 10 European States | Krzysztof Nojszewski |  Received | 
|  | |||
| 14-MT | DIGITAL THERAPEUTICS IN EUROPE: A STRUCTURED REVIEW OF REIMBURSEMENT AND ACCESS PATHWAYS | Alison Howell |  Received | 
|  | |||
| 15-MT | Environmental Impact of Prefilled and Reusable Injectable Systems: A Systematic Review | Matthias Borms |  Received | 
|  | |||
| 15-RWD | Airpollution Signals and National Demand for Asthma Medication in Brazil Between 2018-2023: Should It Be Considered a Public-Health Concern? | Tulio Sarmento |  Received | 
|  | |||
| 16-MSR | Advancing the Science of Qualitative Patient Preference Assessment Using Large Language Models | Emanuel Krebs |  Received | 
|  | |||
| 17-EE | A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK | Antonio Ramirez de Arellano |  Received | 
|  | |||
| 17-PT | Reconsidering Generic Utilities: Implications for Equitable Health Technology Appraisal | Colleen Dumont |  Received | 
|  | |||
| 18-MSR | AI Assistant Meets Human: Refining Methods for Research-Taiilored AI Assistants to Support Global Product Strategy, Decision-Making, and HEOR Impact | Katelyn Keyloun |  Received | 
|  | |||
| 18-RWD | Archival Sample Testing for Real-World Insights: Innovative Approaches to Enriching Retrospective Studies With Biomarker Data | Laura Girardat-Rotar |  Received | 
|  | |||
| 19-EE | A Health Economic Evaluation of Daylight: A Digital Treatment for Anxiety in NHS South Yorkshire | Christopher Miller |  Received | 
|  | |||
| 19-MT | From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment | Gurmit Sandhu |  Received | 
|  | |||
| 19-HTA | Accounting for Bereavement in NICE Pediatric Health Technology Appraisals: A Review of the Inclusion of Caregiver Health Utilities After the Death of a Child | Geoffroy Coteur |  Received | 
|  | |||
| 20-PCR | Are You Implementation Ready? An Alternative Patient And Healthcare System-Centered Model For Pharma | Rita Freitas |  Received | 
|  | |||
| 20-MSR | AI Powered SQL for Real-World Data: From Questions to Insights | Vasileios Kontonis |  Received | 
|  | |||
| 21-MT | Generative A-Powered Extraction of Immunerelated Adverse Events From Oncology Case Reports | Colleen Dumont |  Received | 
|  | |||
| 21-PT | Can Generative AI Deliver Patientfriendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy | Colleen Dumont |  Received | 
|  | |||
| 22-HSD | Characteristics and Treatment of Prevalent Heart Failure in the US: A Cross-Sectional Analysis of Annual Trends From 20142023 | Rachel Knapp |  Received | 
|  | |||
| 22-MSR | AI-Assisted Time-to-Event Projection: A Case Study and Broader Potential | Jack Ishak |  Received | 
|  | |||
| 23-HTA | Addressing Payer Concerns: Opportunities for HEOR in Orphan Drug Development | Weiwei Xu |  Received | 
|  | |||
| 24-HSD | Clinical Characteristics Among Patients Screening for Hepatitis C Virus (HCV) and HCV Positivity Rates, 2020-2024: Analysis of US Real-World Data | Janna Manjelievskaia |  Received | 
|  | |||
| 25-HTA | Advancing a Greener Ecosystem in Health Technology Assessment: A Review of Environmental Integration As an Additional Value Driver | Colleen Dumont |  Received | 
|  | |||
| 25-PT | Systems-level Modelling Approaches for Complex Health Technologies: A Systematic Review | Bora Zwart |  Received | 
|  | |||
| 25-EE | A Novel View on the Treatment Costs of Relapsed or Refractory Diffuse Large B-cell Lymphoma From the Brazilian Private Healthcare System Perspective: A First- to Third-Line Analysis | Frederico Sallum |  Received | 
|  | |||
| 25-CO | Baseline Characteristics and Treatment Persistence in UK Patients With Moderate-to-Severe UC Following 12-week Mirikizumab Induction: Real-World Data From IBD BioResource | John Downey |  Received | 
|  | |||
| 26-MSR | An Update on the Evolving Use of Artificial intelligence and Machine Learning (AI/ML) in Systematic Literature Reviews (SLRs) | Ines Guerra |  Received | 
|  | |||
| 28-MT | Impact of RFID-Enabled Unit-level Traceability on Resource Utilization and Quality Assurance in Prefilled Syringe Production | Matthias Borms |  Received | 
|  | |||
| 28-PT | Crossvalidation of the Glycated Haemoglobin Hba1c Translator: A Predictive Tool to Evaluate the Relationship Between Diabetes Complications and Associated Healthcare Costs | Gina Bloomfield |  Received | 
|  | |||
| 28-MSR | Anchors Away: Navigating Unanchored Indirect Comparisons With Multi-Level Unanchored Meta-Regression (ML-UMR) | Conor Chandler |  Received | 
|  | |||
| 30-PCR | Beyond the Conversation: A Narrative Review of Cost-Informed Shared Decision-Making and Its Impact on Medication Adherence in Chronic Conditions | Sultan Alshurbaji |  Received | 
|  | |||
| 30-SA | Designing Digital Healthcare Professional Surveys: A Methodological Overview | Sally Vincent |  Received | 
|  | |||
| 30-PT | An Exploration of Implementing Herd Immunity Into Static Models for Economic Evaluation of Vaccines | Ruth Chapman |  Received | 
|  | |||
| 32-HSD | Describing the Real-World Burden of Demodex Blepharitis: A Multicentre Audit in a UK Public Specialist Eye Care Setting | Kate Monk |  Received | 
|  | |||
| 33-EPH | Burden of Bloodstream Infections in the United States: Incidence and Healthcare Resource Utilization 2022-2024 | Ning Rosenthal |  Received | 
|  | |||
| 33-CO | Bridging the Regulatory-Payer Evidence Gap: A Case Study With Six Minute Walk Distance and Mortality | Noemi Hummel |  Received | 
|  | |||
| 34-EE | A Systematic Literature Review on Costs and Healthcare Resource Utilization in Spinal Muscular Atrophy | Michel Kroes |  Received | 
|  | |||
| 34-RWD | Clinical Outcomes and Economic Burden of Acute Lower Respiratory Tract Infectionrelated Hospitalizations Among Adults in the United States Post COVID-19 Pandemic | Ning Rosenthal |  Received | 
|  | |||
| 34-PCR | Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries | Anggie Wiyani |  Received | 
|  | |||
| 34-MSR | Artificial Intelligence Detection of National Clinical Practice Gaps in Hormone Sensitive Prostate Cancer HSPC in Brazil: A Patient-Centered Framework | Ming Xuan Lim |  Received | 
|  | |||
| 34-HPR | Barriers and Policy Solutions in Off-Patent Drug Repurposing: A Full-Life-Cycle Perspective | Jaime Espin |  Received | 
|  | |||
| 35-RWD | Clinical Relevance of a Machine Learning Model for Automated Analyses of Depression Severity: The ePHQ-9 in Treatment-Resistant Depression | Jodi Silva |  Received | 
|  | |||
| 35-HPR | Benefits and Challenges in the Implementation of EU HTAR for Medical Devices: Lessons Learned From the Pharmaceutical Industry | Xuanqi Pan |  Received | 
|  | |||
| 35-CO | Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study | Shana Malinski |  Received | 
|  | |||
| 35-EPH | Cardiovascular Event Rate and Mortality Among Primary Prevention Hypercholesterolemia Patients in Japan | Tomohiro Kondo |  Received | 
|  | |||
| 36-HTA | Application of Budget Impact Model in Evaluation of P2p Payment Strategy in US Health Systems | Ashoke Bose |  Received | 
|  | |||
| 36-EPH | Cardiovascular Event Rates and Mortality Among Secondary Prevention Hypercholesterolemia Patients in Japan | Tomohiro Kondo |  Received | 
|  | |||
| 37-MT | Robotic Surgery: A Budget Analysis in the Italian Healthcare Setting | Elisa Tacconi |  Received | 
|  | |||
| 38-EPH | Care of Patients With Phenylketonuria (PKU) in Germany a Claims Data Analysis From 2013 to 2023 | Axel Boehnke |  Received | 
|  | |||
| 38-HSD | Economic Burden and Healthcare Resource Utilization of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Germany: A Claims Data Analysis | Yestle Kim |  Received | 
|  | |||
| 38-SA | Enhancing Targeted Literature Reviews (TLRs) with Artificial Intelligence (AI): A Methodological Approach for Conducting Efficient Targeted Searches | Caroline von Wilamowitz-Moellendorff |  Received | 
|  | |||
| 38-PCR | Care Partner Burden and Experiences With Schizophrenia: A National Canadian Survey | Raymond Milan |  Received | 
|  | |||
| 39-MSR | Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer | Darren Johnson |  Received | 
|  | |||
| 41-RWD | Comparing the Addition of Natural Language Processing (NLP) to US Electronic Health Records (HER): Insights Into Extracting Predicted Forced Vital Capacity Ppfvc From Unstructured Clinical Notes | Janna Manjelievskaia |  Received | 
|  | |||
| 41-SA | Factors Associated With the Publication of Real-World Evidence Studies in Lung Cancer by Journal Impact Factor | Elizabeth Harvey |  Received | 
|  | |||
| 42-SA | Feasibility Assessment of a Real-World Comparator Cohort Using Multiple Qualifying Index Lines of Therapy (LOTs) in Third-line or Later (3L+) Diffuse Large B-cell Lymphoma (DLBCL) | Michael Wallington |  Received | 
|  | |||
| 42-MSR | Automating PICOs Criteria Assessment in Systematic Reviews With LLMs: Insights From Two Case Studies | Ines Guerra |  Received | 
|  | |||
| 42-MT | The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower | Gareth Obery |  Received | 
|  | |||
| 42-HTA | Artificial Intelligence in Pharmaceutical Payer Decision Making- Assessing Current Use, Strategic Intent, and Infrastructure Readiness | Rahael Maladwala |  Received | 
|  | |||
| 43-CO | Clinical Burden and Transfusionrelated Outcomes in Transfusion-dependent Thalassemia in the Kingdom of Saudi Arabia and United Arab Emirates | Vanessa Shih |  Received | 
|  | |||
| 43-EPH | Characterizing Polycystic Ovary Syndrome (PCOS) and Related Diagnoses Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025 | Janna Manjelievskaia |  Received | 
|  | |||
| 43-HTA | Artificial Intelligence-based Population, Intervention, Comparator, and Outcome (PICO) Prediction for European Union (EU) Joint Clinical Assessment (JCA) | Gavin Outteridge |  Received | 
|  | |||
| 44-PCR | CKDL5 Deficiency Disorder: Caregiver´s Perception of Clinical Symptoms Disease Management and Its Impact on Quality-of-life | Ficara Valentine |  Received | 
|  | |||
| 44-CO | Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review | Isabelle Lundqvist |  Received | 
|  | |||
| 44-EE | All-Cause Healthcare Resource Use in Recurrent Respiratory Papillomatosis: A Claims-based Comparison With Matched Controls | Barkha Patel |  Received | 
|  | |||
| 46-HTA | Assessing the Value of the Enzyme Replacement Therapy for Hypophosphatasia (HPP): A Spanish Sub-analysis of a Pan-European Multidisciplinary Multi-Criteria Decision Analysis (MCDA) | Sandra Merino-Montero |  Received | 
|  | |||
| 47-MSR | BHM and BHM-Based Extrapolations in an HTA Framework | Katrin Haeussler |  Received | 
|  | |||
| 48-PCR | Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Health Care (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC) | Jenya Antonova |  Received | 
|  | |||
| 50-CO | Clinical Profile of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Treated With Complement Inhibitors: Results From a Real-World Study | Anggie Wiyani |  Received | 
|  | |||
| 51-HPR | Comparison of the Early Access and Postmarket Evaluation Systems in South Korea and Germany´s DIGA | MINJEONG JO |  Received | 
|  | |||
| 53-MSR | Can Generative Artificial Intelligence (GenAI) Be Leveraged to Automate Scoping Searches of Systematic Literature Reviews (SLRs)? | Ines Guerra |  Received | 
|  | |||
| 53-HTA | Beyond Productivity: How Professional Identity Shapes Generative AI Adoption Among Medical Writing Professionals | Pia Cuk |  Received | 
|  | |||
| 53-EE | Early Outpatient Follow-Up and reduced Health Care Resource Utilization in Acute Heart Failure in Germany: A descriptive Analysis | Thomas Staab |  Received | 
|  | |||
| 54-SA | Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC) | Franziska Dirnberger |  Received | 
|  | |||
| 56-HTA | Beyond the Surface: Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations | Heather Cameron |  Received | 
|  | |||
| 56-CO | Comparative Efficacy of Asciminib Versus Second Generation TKIs in Newly Diagnosed Phcml Using Unanchored Matching-Adjusted Indirect Comparisons | Isabelle Lundqvist |  Received | 
|  | |||
| 56-PCR | Describing the Burden of RSV Infection and Subsequent Wheezing in Toddlers: An International Cross-Sectional Study | Ficara Valentine |  Received | 
|  | |||
| 57-RWD | Design Operating Characteristics in a Non-Interventional Study Framework | Charlotte Wilhelm-Benartzi |  Received | 
|  | |||
| 58-PCR | Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version | Ufuk Coskun |  Received | 
|  | |||
| 58-CO | Comparative Efficacy of Iptacopan Monotherapy Vs Danicopan Add-on to C5i in Paroxysmal Nocturnal Hemoglobinuria (PNH) Results From an Indirect Treatment Comparison (ITC) | Anggie Wiyani |  Received | 
|  | |||
| 58-EE | Assessing the Budget Impact of Bimekizumab in the Management of Hidradenitis Suppurativa in France | Costello Medical |  Received | 
|  | |||
| 59-PCR | Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer | Jessica Nicholson |  Received | 
|  | |||
| 59-MSR | Comparing Key European HTA Body Methodological Standards for Systematic Reviews of Economic and Utility Evidence | Yogesh Punekar |  Received | 
|  | |||
| 59-CO | Comparative Efficacy Safety and Discontinuation of Inhaled Levodopa for Patients With Parkinson´s Disease: A Network Meta-Analysis | Kate Monk |  Received | 
|  | |||
| 59-SA | Laboratory Testing Patterns in Patients With Breast Cancer Treated With CDK4/6 Inhibitors: A Multi-Country Electronic Health Record Study From the UK Germany and Japan | Darren Johnson |  Received | 
|  | |||
| 60-RWD | Development and Implementation of a Dynamic Framework for Assessment and Improvement of Registries´ Data Quality | Mai Duong |  Received | 
|  | |||
| 62-PCR | Development of the Adelphi Caregiver Experience Questionnaire© (ACARE): A Novel Tool Designed to Measure and Understand the Burden and Quality of Life Impacts of the Caregiver Role | Gavin Dickie |  Received | 
|  | |||
| 65-HSD | Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India | Ankit Ghildiyal |  Received | 
|  | |||
| 65-EPH | Drivers of Improvement in Observed Survival in Malignant Cancer Sites: A Cancer Registry Analysis | Lauren Rengger |  Received | 
|  | |||
| 65-PCR | Diagnostic Odyssey of Patients With the Rare Immunodeficiency Activated Pi3 Kinase Delta Syndrome APDS: Case Study With Expert Interviews and Patient Surveys | Roman Spelsberg |  Received | 
|  | |||
| 66-RWD | Disease Severity at Advanced Therapy Initiation in Real-World Psoriasis Patients in the US | Jodi Silva |  Received | 
|  | |||
| 66-HSD | Is There Sufficient Economic Evidence for Reimbursing Behavioral Interventions? A Targeted Literature Review | Andrew Kwist |  Received | 
|  | |||
| 67-EE | Assessment Of Health State Utilities Associated With Treatment For Chronic Hepatitis B Virus HBV Infection | Louis Matza |  Received | 
|  | |||
| 67-PCR | Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study | Fang Zhou |  Received | 
|  | |||
| 68-HTA | Challenges and Opportunities in the Dutch Lock Procedure Improving Access and Reimbursement Timelines for Cell and Gene Therapies in the Netherlands | Angela Borghouts- de Ruijter |  Received | 
|  | |||
| 71-HPR | Estimating Lost Life-years and Quality-Adjusted Life-years of Undertreatment of Patients With Renal Cell Carcinoma and Metastatic Pancreatic Cancer in England | Vladislav Berdunov |  Received | 
|  | |||
| 73-HTA | Challenges in the German AMNOG Procedure: The Need for National PICO Transparency and Optimized Consultation Windows in the Context of EU-HTA | Hanna Bayer |  Received | 
|  | |||
| 74-CO | Dinutuximab Beta Versus Historical Controls in the Maintenance Therapy of Relapsed Neuroblastoma: Unadjusted and Adjusted Indirect Comparison | Fabian Schmidt |  Received | 
|  | |||
| 74-EE | Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective | Ezinne Byrne |  Received | 
|  | |||
| 75-PCR | Enhancing Understanding of Quality of Life in Multiple Sclerosis Through Social Listening: Complementing Traditional HRQoL Measures | Jackie Cuyvers |  Received | 
|  | |||
| 75-MSR | AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs | Kate Monk |  Received | 
|  | |||
| 75-CO | Disease Progression Modelling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D) | Sandra Merino-Montero |  Received | 
|  | |||
| 76-HSD | Modelling the Environmental and Cost Impact of a Novel Detergent in NHS Endoscope Reprocessing Workflows | mutsa mutowo |  Received | 
|  | |||
| 77-HSD | Number of Inquiries for a Second Course of Teprotumumab in the US Over Four Years | Alexandra Eddy |  Received | 
|  | |||
| 77-HTA | Comparative Analysis of Economic Evaluation Frameworks for AI-Based Digital Health Technologies Across Four HTA Systems | EUNKYEONG BAE |  Received | 
|  | |||
| 78-PCR | Establishing the Relationship Between the Worst Itch Numerical Rating Scale and EQ-5D Utility in Patients With Primary Biliary Cholangitis Experiencing Pruritus: Pooled Results From GLIMMER and the PRO Validation Study | Irina Proskorovsky |  Received | 
|  | |||
| 79-CO | Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-Analysis and Discussion of Appropriate Methodology | Barnaby Hunt |  Received | 
|  | |||
| 79-HSD | Optimizing Workforce Efficiency and Reducing Waiting Lists Through Remote Monitoring in Obstructive Sleep Apnea (OSA) Care in NHS | Ankit Ghildiyal |  Received | 
|  | |||
| 80-SA | Real-World Cancer Treatments for Common Solid Tumors in China: A Targeted Literature Review | Mireia Raluy Callado |  Received | 
|  | |||
| 81-HTA | Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access? | Colleen Dumont |  Received | 
|  | |||
| 81-HSD | Overcoming Patient Access Barriers in Complex Conditions: Lessons From Schizophrenia for Broader Healthcare Applications | Bregt Kappelhoff |  Received | 
|  | |||
| 81-HPR | Evolution of National Price Negotiations for Pharmacy/Retail Medicines (Triparty Negotiations) in Sweden and Implications for Access | Anja Wikström |  Received | 
|  | |||
| 81-MSR | Effect of Positive Airway Pressure Therapy on Mortality in European Obstructive Sleep Apnea Patients: Post Hoc Analysis of a Global Meta-Analysis | Ankit Ghildiyal |  Received | 
|  | |||
| 82-RWD | Expediting Oncology Evidence Generation by Leveraging Emrenabled Clinically-rich Real-World Data at Scale | Laura Girardat-Rotar |  Received | 
|  | |||
| 84-RWD | Feasibility Assessment of Real-World Data for Trial Emulations: A Methodological Framework | Colleen Dumont |  Received | 
|  | |||
| 85-HTA | Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets? | Nikhil Taxak |  Received | 
|  | |||
| 85-EPH | Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States | Noemi Hummel |  Received | 
|  | |||
| 86-MSR | Ensuring Patient Inclusion When Baseline Is Missing: Utilizing Constrained Longitudinal Data Analysis Clda for Patient Reported Outcomes (PROs) | Hannah Fairbanks |  Received | 
|  | |||
| 86-RWD | From Clinic to Cohort: The VOICE Vitiligo Registry and Bioresource As a Blueprint for High-Fidelity Specialist Registries | Charlotte Curtis |  Received | 
|  | |||
| 88-HTA | Confidential Prices in NICE Health Technology Assessment: How Common Are They? | Sarah Wilkes |  Received | 
|  | |||
| 88-EPH | Estimating the Future Burden of Unvaccinated Girls Against Human Papilloma Virus (HPV) in Europe: A Modeling Study | Ugne Sabale |  Received | 
|  | |||
| 88-PCR | Explaining Psychiatric Co-morbidities in Patients With Skin Conditions: The Importance of Clinical Characteristics and Patient-Reported Disease Impact | Allison FitzGerald |  Received | 
|  | |||
| 88-CO | Effectiveness of Subcutaneous Natalizumab in Multiple Sclerosis: Real-World Evidence From a Finnish Registry Study | Peter Oliver-Smith |  Received | 
|  | |||
| 89-CO | Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pre-treated Breast Cancer: A Systematic Literature Review (SLR) | Patricia Dorling |  Received | 
|  | |||
| 89-HTA | CONITEC in Action: A Trend Analysis of Conitec´s Evaluation Outcomes From 2020 to Present Day | Dominika Meszarosova |  Received | 
|  | |||
| 90-CO | Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in pre-treated locally advanced/metastatic (LA/m) Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR) | Patricia Dorling |  Received | 
|  | |||
| 92-EE | Budget Impact Analysis of Obecabtagene Autoleucel for Adults With Relapsed/Refractory B-cell ALL From a US Payer Perspective | David Bertwistle |  Received | 
|  | |||
| 92-HTA | Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAI) and Ventilatorassociatedhospitalacquired Pneumonia (HAP/VAP) Caused by Suspected MBL-producing Enterobacte | Sheng-Tzu Hung |  Received | 
|  | |||
| 93-SA | The Health Economic Case for AI in Radiology: A Systematic Review and Appraisal of Evaluation Quality and Methods | Lucy Gregory |  Received | 
|  | |||
| 94-RWD | Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data | Weiying Wang |  Received | 
|  | |||
| 94-PCR | Exploring the Promise of Generative AI for Coding and analyzing Qualitative Patient Data: Results From a Pilot Study in Non-Hodgkin´s Lymphoma | Karen Bailey |  Received | 
|  | |||
| 95-EPH | Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024) | Colleen Dumont |  Received | 
|  | |||
| 95-HTA | Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages | Sheng-Tzu Hung |  Received | 
|  | |||
| 95-HPR | Financial Impact of EU MDR Compliance: A Cost Mapping Assessment for Manufacturers | Aleksandra Kozlova |  Received | 
|  | |||
| 96-HPR | Fit-for-purpose Real-World Data: Lessons From FDA QCARD and EMA Data Quality Framework | Darren Johnson |  Received | 
|  | |||
| 97-HTA | Cost-Effectiveness Modelling Challenges and Trends in the Neoadjuvant and Perioperative Settings: A Review of NICE Oncology Submissions | Chloi Theriou |  Received | 
|  | |||
| 100-CO | EQ-5D Utility Impact of Worsening NYHA Class and CV Hospitalization (CVH) on Health-Related Quality of Life (HRQoL) of Patients With ATTR-CM Based on the ATTRibute-CM Trial | Irina Proskorovsky |  Received | 
|  | |||
| 101-RWD | Improving Data Quality in Oncology Electronic Health Record (HER)-Derived Databases for Research and Regulatory Decision-Making | Zhaohui Su |  Received | 
|  | |||
| 101-SA | Using a Large Language Model LLM for Data Extraction of Studies: Learnings From a Targeted Literature Review TLR in Non-Small Cell Lung Cancer (NSCLC) | Caroline von Wilamowitz-Moellendorff |  Received | 
|  | |||
| 102-CO | Estimating the Mean Time in Treatment Free Remission for Patients in Early Line CML | Isabelle Lundqvist |  Received | 
|  | |||
| 103-HTA | Defining Unavoidable Uncertainty in HTA: Towards More Flexible and Adapted Approaches for Promising Treatments | Dimitri Pouradier Duteil |  Received | 
|  | |||
| 103-MSR | Exploring Meaningful Change in Digital Health Technologies via Qualitative Interviews | Elizabeth Collins |  Received | 
|  | |||
| 103-HSD | Standardizing Point-of-care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform | Maura Leusder |  Received | 
|  | |||
| 104-MSR | Exploring Non-Proportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology | Chloe Spalding |  Received | 
|  | |||
| 104-PCR | Harnessing Digital Patient Monitoring and Primary Care Records to Map the Disease Burden of Multiple Myeloma in the United Kingdom | Kim Summers |  Received | 
|  | |||
| 106-SA | Work Productivity Loss Among Caregivers of Pediatric Patients With COVID-19 OR Influenzainfluenzalikeillness: A Systematic Literature Review | Jingyan Yang |  Received | 
|  | |||
| 108-HPR | Global Payer Policies Potentially Impacting Pharma Pricing and Market Access Strategies: A Review of Five Key Trends Shaping Pharma Future | Nikhil Taxak |  Received | 
|  | |||
| 110-EE | Budget Impact of Metyrapone for the Treatment of Cushing´s Syndrome in France | Mariam SBEITY |  Received | 
|  | |||
| 110-RWD | Integrating Prospective and Retrospective Real-World Data to Construct External Comparator Arms: Novel Methods and Design Considerations | Benjamin Ackerman |  Received | 
|  | |||
| 111-PCR | Healthcare Professionals-Perceived Benefits and Opportunities to Improve an Electronic Patient Reported Outcomes (ePRO) Based Remote Symptom Monitoring (RSM) Program During Cancer Treatment | Renae Neumann |  Received | 
|  | |||
| 111-EPH | Five Year Inpatient Hospital Trends of COVID-19 Admissions in US Medicare Fee for Service | peter kardel |  Received | 
|  | |||
| 112-HPR | Health Halo Effect in Supplement Marketing: A Content Analysis of Medical Claims in Community Pharmacies | Marwan Alrasheed |  Received | 
|  | |||
| 113-RWD | Landscape of Natural Language Processing (NLP) Capabilities at Clinical Sites: Insights From a Real-World RW Gastric Cancer (GC) Study | Julia Gallinaro |  Received | 
|  | |||
| 114-EPH | Generating Data for Diversity Planning in Breast Cancer: A Multi-Database Validation Study Using US Claims and HER, Population Census, and Cancer Registry Data in the United States | Alison Isherwood |  Received | 
|  | |||
| 115-PCR | Health-Related Quality of Life for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan | Jade Garratt-Wheeldon |  Received | 
|  | |||
| 116-RWD | Leveraging a Multi-Country Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe | Jasper Deuring |  Received | 
|  | |||
| 116-PCR | Health-Related Quality of Life in First-Line Advanced or Metastatic Non-Small Cell Lung Cancer: A Systematic Review With Focus on the PD-L1 Negative Subgroup | Colleen Dumont |  Received | 
|  | |||
| 118-RWD | Leveraging Large-Language Models for Medical Code List Creation: An Example Using the Charlson Comorbidity Index | Andreas Ochs |  Received | 
|  | |||
| 118-EE | Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study | Chiranjit Ghosh |  Received | 
|  | |||
| 118-HSD | Trends in Receipt of Preventive Healthcare Services from 2020-2024: US Electronic Health Records (EHR) Database Analysis of 118 Million Patients | Janna Manjelievskaia |  Received | 
|  | |||
| 119-HSD | Understanding Trends and Opinions on More Environmentally-friendly Health Care: A Clinician Survey | Kinga Marczell |  Received | 
|  | |||
| 120-HTA | Economic Assessments of Rare Disease Drugs in France: Insights From CEESP Opinions Reviews | Colleen Dumont |  Received | 
|  | |||
| 123-HPR | Innovation in Off-Patent Competitive Environment: Key Learnings From Successes and Failures | Richard Mee |  Received | 
|  | |||
| 125-CO | Garbage In, Garbage Out: Can AI Reduce the Impact of Human Error in eCOA Localized Text Migration? | Jonathan Norman |  Received | 
|  | |||
| 125-RWD | Millennial Medical Record Data Profile: A Japanese Electronic Medical Records Database Utilising Unstructured Data for Lung Cancer Research | Ayumi Hamaguchi |  Received | 
|  | |||
| 126-MSR | Identifying Risk Profiles for Early Treatment Discontinuation in Geographic Atrophy Using Machine Learning and SHAP Clustering | Ashwin Rai |  Received | 
|  | |||
| 126-PCR | Identifying Patient-Reported Outcome Measures to Capture Patients´ Experiences of Symptoms and Impacts of Acute Myeloid Leukaemia (AML) | Isabelle Petit-Delattre |  Received | 
|  | |||
| 126-EPH | Higher Mortality for Generalized Pustular Psoriasis Compared With Plaque Psoriasis Highlights the Need for Improved Treatments: Insights From a Meta-Analysis | Helen Miller |  Received | 
|  | |||
| 127-PCR | Identifying Patient-Reported Outcome Measures to Capture Patients´ Experiences of Symptoms and Impacts of Myelodysplastic Syndromes (MDS) | Isabelle Petit-Delattre |  Received | 
|  | |||
| 127-MSR | Implementing Simultaneous Maximum Acceptable Risk Thresholds (SMARTs) in Discrete Choice Experiments (DCE): A Feasible Approach to Quantify Tolerance for Multiple Risks | Natalie Land |  Received | 
|  | |||
| 129-RWD | Occupational Disease Claims and Payments in Indonesia: Insights From Administrative Data 2018 2022 | Levina Chandra Khoe |  Received | 
|  | |||
| 129-CO | Healthcare Resource Utilization and Disease Progression in Patients With Primary Hyperoxaluria: A Retrospective Cohort Study | Nicole Carroll |  Received | 
|  | |||
| 130-EPH | Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends | Naomi Sacks |  Received | 
|  | |||
| 130-EE | Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High Efficacy Disease Modifying Therapy in Mexico | Margarita Fuentes |  Received | 
|  | |||
| 130-MSR | Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method | Martin Scott |  Received | 
|  | |||
| 131-PCR | Impact of Non-Transfusion-Dependent Thalassemia on Adult Patients´ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates | Vanessa Shih |  Received | 
|  | |||
| 132-HPR | Levelling the Field: How the MFN Could Transform Drug Pricing? | Rebecca Andrews |  Received | 
|  | |||
| 132-HTA | Evaluating High-Cost Gene Therapies for Non-Cancer Conditions: Insights From NICE´s Standard Appraisal Process | Naomi Stapleton |  Received | 
|  | |||
| 133-PCR | Impact of Transfusion-Dependent Thalassemia on Adult Patients´ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates | Vanessa Shih |  Received | 
|  | |||
| 133-EE | Clinical Management and Outcomes of Patients in England With eGFR Mutation Positive Non-Small Cell Lung Cancer: A Retrospective Observational Study and Its Impact on UK Health Technology Assessments | Elise Bell |  Received | 
|  | |||
| 133-RWD | Parental Vaccine Hesitancy in Children With Co-morbidities: A Comparative Analysis | Anar Murphy |  Received | 
|  | |||
| 134-HTA | Evaluating the Role of Patient Opinion in NICE Decision-Making for Rare Disease Appraisals: A Review of Committee Papers and Final Guidance | Lauren Rengger |  Received | 
|  | |||
| 135-MSR | Key Risk Indicators in eCOA: Considerations for Improving eDiary Data Quality and Regulatory Compliance | Ingeborg de Gooijer |  Received | 
|  | |||
| 136-HTA | Evaluating the Value Elements Considered in Health Technology Assessments of Paroxysmal Nocturnal Hemoglobinuria Treatments: A Targeted Review | Anggie Wiyani |  Received | 
|  | |||
| 136-PCR | Improving the Conceptual Coverage of the 15-item Penn Parkinson´s Daily Activity Questionnaire (PDAQ-15) for Use in the Mild-to-Moderate Lewy Body Dementia Population | Laure Delbecque |  Received | 
|  | |||
| 137-MSR | Leveraging NLP to Characterize Real-World Triptan Use and Adherence From Unstructured EHR | Sunny Guin |  Received | 
|  | |||
| 137-HTA | Evidence of Mapping Malpractice? A Review of Mapping Algorithm Usage in NICE Health Technology Appraisals | George Bungey |  Received | 
|  | |||
| 138-EPH | Important Risk Factors to Proxies of Treatment Failures in Patients With Major Depressive Disorder: Insights From a Claims Database Study | Ling Zhang |  Received | 
|  | |||
| 141-EE | Comparing Alternative Extrapolation Methods Using Standard Partitioned Survival Model Functionality in the Presence of Converging Survival Data: A Case Study in Renal Cell Carcinoma | George Bungey |  Received | 
|  | |||
| 141-HTA | Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions | Colleen Dumont |  Received | 
|  | |||
| 142-CO | Impact of Tafamidis Use in Colombian Patients Diagnosed With ATTR-CM on Health-Related Quality of Life During One Year of Follow-up: Real-World Study in Colombia | Juan Manuel Reyes Sanchez |  Received | 
|  | |||
| 142-MSR | Machine Learning to Predict Noncompliance and Program Dropout in Patients Treated for Chronic Diseases: Unsupervised and Supervised Analyses From a Large Multi-national Drug Access Program Database | Mariana Rodrigues |  Received | 
|  | |||
| 142-EE | Comparing the Economic Burden in Patients With versus Without Ehlers-Danlos Syndrome (EDS) Using a Large US Electronic Health Records Database | Janna Manjelievskaia |  Received | 
|  | |||
| 143-MSR | Matching Adjusted Indirect Comparison Of Asciminib vs Flumatinib As First-Line Treatment for Chronic Myeloid Leukemia in China | Xue Gao |  Received | 
|  | |||
| 143-EE | Comparison of Non-Statin Lipid-Lowering Therapies (LLTs) by Their Annual Cost per Effectively Treated Very High-Risk Patient in Spain | Vanessa Gómez Navarro |  Received | 
|  | |||
| 143-EPH | Incidence of Neutropenia Adverse Events Identified in Electronic Health Care Records Among Initiators of CDK4/6 Inhibitors With Advanced Breast Cancer in the UK | Darren Johnson |  Received | 
|  | |||
| 145-EPH | Increases in Frailty Following Hospitalization With COVID-19: An Analysis of Claims and Annual Health Check Data | Paul McDwyer |  Received | 
|  | |||
| 145-RWD | Real-World Insights From the LOGEX IMID Observatory: A Multi-Country, Multi-Year Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases | Jasper Deuring |  Received | 
|  | |||
| 147-MSR | Methods for Incidence Progression Estimation in Partitioned Survival Analysis: Does the Chosen Method Matter? | George Bungey |  Received | 
|  | |||
| 148-PCR | Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States | Barkha Patel |  Received | 
|  | |||
| 148-HTA | Fractional Polynomial Survival Models in HTA: An Exploratory Review of Use and Methodological Guidance Across Global Agencies | Andre Verhoek |  Received | 
|  | |||
| 148-EE | Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review | Ramon Oliveira |  Received | 
|  | |||
| 149-RWD | Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data | Christian Atkinson |  Received | 
|  | |||
| 150-HTA | From Evidence Gaps to Launch Delays: A Review of Health Technology Assessment Critiques and Health Economics and Outcomes Research Strategy Readiness | Weiwei Xu |  Received | 
|  | |||
| 150-MSR | Modelling Physician Prescribing Decisions Based on Patient Characteristics for Positioning of a Novel Treatment Entering a Well-Established Category | Sarah-Jane Cashmore |  Received | 
|  | |||
| 151-PCR | Mapping the Evidence on Interrelationships Between Cancer Stage Financial Toxicity (FT) and Health-Related Quality of Life (HRQoL) | Ali Tafazzoli |  Received | 
|  | |||
| 152-CO | Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe | Helen Miller |  Received | 
|  | |||
| 152-MSR | Natural History of Creutzfeldt-Jakob Disease: A Comparison of Manual Versus Manual Plus AI-Assisted Approaches in Literature Review | Setareh Williams |  Received | 
|  | |||
| 153-HPR | Orphan Drugs Availability in Israel: A Base for Policy Development | Daphna Arbel |  Received | 
|  | |||
| 153-EE | Constructing a Dynamic Budget Impact Model: An AI Pre-Training Approach for a New Parkinson´s Disease Drug | Nicholas Yulin Chen |  Received | 
|  | |||
| 153-HTA | From Insight to Impact: Rethinking Pharma-Payer Partnerships to Enable Future Access in Europe | Alexandra Guyenet |  Received | 
|  | |||
| 153-RWD | Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions | Nadia Quignot |  Received | 
|  | |||
| 154-HTA | From JCA to Local PR: Evaluating Impact Across Europe | Varol N. |  Received | 
|  | |||
| 155-MSR | New Developments in the Psychometric Testing of the Patient-Reported Impact of Dermatological Diseases (PRIDD) Questionnaire: Responsiveness and Minimally Important Change | Allison FitzGerald |  Received | 
|  | |||
| 157-EE | Cost and Healthcare Resource Utilisation Associated with Chronic Inducible Urticaria: A Targeted Literature Review | Mukhtar Ahmad Dar |  Received | 
|  | |||
| 158-EE | Cost Calculator of Immunotherapies in 1L Endometrial Cancer Treatment for the Deficient Mismatch Repair Proficient Mismatch Repair and Intentiontotreat Populations From the Brazilian Private Healthcare System | Dipika Morgan |  Received | 
|  | |||
| 158-HTA | From Theory to Practice: Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models | George Bungey |  Received | 
|  | |||
| 158-CO | Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study | Colleen Dumont |  Received | 
|  | |||
| 159-PCR | Mental and Behavioral Health Disorders MBHD Among Patients With Metastatic and Non-Metastatic Cancer: A Claims-based Analysis | Ali Tafazzoli |  Received | 
|  | |||
| 159-EE | Cost Comparison of Symptom Treatment in Atopic Dermatitis Using Upadacitinib and Dupilumab in Poland | Karolina Dziadek |  Received | 
|  | |||
| 159-RWD | Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data | Darren Johnson |  Received | 
|  | |||
| 160-MSR | Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements | Annett KUCKA |  Received | 
|  | |||
| 160-HPR | Healthcare Professionals´´ Views on Implementing Generic and Biosimilar Medicines´ Policies | Kefah Alqawasmeh |  Received | 
|  | |||
| 161-RWD | Real-World Insights Into Prostate Cancer Management Using Electronic Health Record-Derived Data From the UK | Darren Johnson |  Received | 
|  | |||
| 161-HPR | Physicians´ Knowledge, Attitude, and Practice Regarding Medical Liability: A Study in Saudi Arabia | Mohamed AlQurashi |  Received | 
|  | |||
| 162-HTA | German HTA Outcomes for Rare Disease Drugs When EMA Orphan Designation Does Not Legally Determine Added Benefit | Daniela Tummoscheit |  Received | 
|  | |||
| 162-HPR | Predicting the Maximum Fair Price (MFP) From Medicare Negotiations | Louisa Oliver Byrne |  Received | 
|  | |||
| 162-CO | Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long Term Prophylaxis in Hereditary Angioedema | Amrita Debnath |  Received | 
|  | |||
| 163-CO | Matching-Adjusted Indirect Comparison of Obecabtagene Autoleucel Versus Blinatumomab Inotuzumab Ozogamicin and Ponatinib in Relapsed or Refractory Adult B-cell Acute Lymphoblastic Leukaemia | David Bertwistle |  Received | 
|  | |||
| 165-EE | Cost Effectiveness Analysis of Trizepataide for the Treatment of Type 2 Diabetes Mellitus in Saudi Arabia | Ahmed Alghamdi |  Received | 
|  | |||
| 166-MSR | Personalized Treatment Optimization Using Reinforcement Learning on Real-World Data (RWD) | Evangelos Vagianos |  Received | 
|  | |||
| 168-PCR | Pain and Fatigue Assessment and Evaluation in Oncology Trials | Paul Cordero |  Received | 
|  | |||
| 169-EPH | Negative Symptoms in Schizophrenia: An Observational Study of Patient Characteristics Cost and Healthcare Resource Utilization From a US Healthcare Database | Jing Zhao |  Received | 
|  | |||
| 169-CO | Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line 2L+ Treatments in Extensive Stage Small Cell Lung Cancer ES-SCLC | Jingyi Liu |  Received | 
|  | |||
| 170-HTA | Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade? | Samantha James |  Received | 
|  | |||
| 170-PCR | Patient and Societal Preferences for On-Demand Treatment in Hereditary Angioedema: Estimation of Utility Using a Discrete Choice Experiment | Latasha Avery |  Received | 
|  | |||
| 172-CO | Nutritional Profile and Cost Evaluation of Elderly Patients in Home Care Within the Brazilian Private Health Sector: A Retrospective Study | Erica Camargo |  Received | 
|  | |||
| 173-HPR | Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review | Viviana Hernandez |  Received | 
|  | |||
| 173-PCR | Patient Perspectives on Disease Experiences and Value of Real-Time Self-Reported Symptom and Treatment Monitoring in Locally Advanced and Metastatic Breast Cancer | Ainsley Belisle |  Received | 
|  | |||
| 174-EE | Cost Implications of Declining MMR Coverage in England: Modelling NHS Burden and the Value of Catch-Up Vaccination | Ruth Chapman |  Received | 
|  | |||
| 174-CO | Overall Survival With Second-generation Androgen-Receptor Signaling Inhibitors in Patients With Metastatic Castration Resistant Prostate Cancer: An Umbrella Review | Immaculate Nevis |  Received | 
|  | |||
| 175-HTA | Health Technology Assessment of Emicizumab for Pediatric Hemophilia A From a Hospital Perspective | Bruno Boietti |  Received | 
|  | |||
| 175-PCR | Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care | Valentine Ficara |  Received | 
|  | |||
| 176-PCR | Patient Perspectives on Unmet Needs in mCRPC: Emphasizing Improved Quality of Life and Delay in Chemotherapy | Valéry Risson |  Received | 
|  | |||
| 177-HTA | Healthstate Utilities for Hormone Receptorpositive Hrhuman Epidermal Growth Factor Receptor 2negative HER2 Breast Cancer | Alison Davie |  Received | 
|  | |||
| 177-RWD | Switching Within vs. Outside the TNFi Class Following TNFi Failure in Patients With Crohn´s Disease (CD) in Europe: A Meta-Analysis of Real-World Outcomes | OTTAVIO SECCHI |  Received | 
|  | |||
| 179-RWD | The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study | Helen Miller |  Received | 
|  | |||
| 181-EPH | Population Characteristics of a Large, Linked Mother-Child EHR Dataset From Truveta | Sunny Guin |  Received | 
|  | |||
| 184-EPH | Pre-Diabetes Prevalence and Progression in the UAE: Insights for Early Intervention and Resource Optimization | João Carapinha |  Received | 
|  | |||
| 184-HPR | Single-Arm Trials and Reimbursement Decision-Making in Europe: A Case Study in Non-Small Cell Lung Cancer | Giles Monnickendam |  Received | 
|  | |||
| 184-EE | Cost per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom | Ezinne Byrne |  Received | 
|  | |||
| 185-PCR | Perspectives of Patients and Caregivers on Relapsed/Refractory Acute Myeloid Leukemia Treatments: A Mixed-Methods Interview Study | Paul Cordero |  Received | 
|  | |||
| 186-EPH | Premature Cancer Related Morbidity and Mortality in Israel: Years Lived With Disability and Years of Life Lost Productivity Costs | Bernadette Pöllinger |  Received | 
|  | |||
| 187-EPH | Premature Mortality and Lost Productivity Due to HPV-related Cancers in Europe | Ugne Sabale |  Received | 
|  | |||
| 188-EE | Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in the US | Alexandra Guyenet |  Received | 
|  | |||
| 189-HTA | HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets | Nikhil Taxak |  Received | 
|  | |||
| 189-HPR | Stakeholder Mapping and Policy Assessment of Rare Diseases in Southeast Asia | Anand Jha |  Received | 
|  | |||
| 192-PCR | Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey | Michael Hurst |  Received | 
|  | |||
| 195-HTA | Impact of the Societal Perspective on HTA Decision-Making in Rare Diseases | Kate Monk |  Received | 
|  | |||
| 196-EPH | Public Health and Economic Impact of RSVpreF Maternal Vaccination Among Infants in Five Asian Countries | Rengina Kefalogianni |  Received | 
|  | |||
| 197-EPH | Public Health and Economic Impact of RSVpreF Vaccination Among Older Adults in Latin America and the Caribbean | Rengina Kefalogianni |  Received | 
|  | |||
| 202-EE | Cost-Effectiveness Analysis of Generalizing Reimbursement the Lp(a) Testing in Secondary Prevention in a Population of French Patients With Cardiovascular Disease | victor Vega |  Received | 
|  | |||
| 202-MSR | The Statistical Abyss: Real-World Evidence for Health Technology Assessment | Martin Scott |  Received | 
|  | |||
| 202-EPH | Quantifying the Economic Burden of Undiagnosed Sleep Apnea in India´s Productive Population: A Health Economic Modeling Approach | Ankit Ghildiyal |  Received | 
|  | |||
| 202-CO | Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients with Type 2 Diabetes: An Observational, Single-Arm, Multicentre, Retrospective Cohort Study (REALISED) | Woralak Chumchujan |  Received | 
|  | |||
| 205-CO | Real-World Evidence on the Broader Benefits of GLP-1 RA-based Therapies: A Global Targeted Literature Review | Katherine Gibbs |  Received | 
|  | |||
| 205-HTA | Integrating Health Equity Into Health Technology Assessment: A Scoping Review | Haneen Aljamal |  Received | 
|  | |||
| 205-MSR | Transportability of Overall Survival Estimates From the United States to Germany in eGFR+ Advanced NSCLC Patients Post-Tyrosine Kinase Inhibitor (TKI) Treatment | Colleen Dumont |  Received | 
|  | |||
| 205-EE | Cost-Effectiveness Analysis of Inhaled Levodopa for Managing OFF Episodes in Patients With Parkinson´s Disease | Kate Monk |  Received | 
|  | |||
| 205-PCR | Real-World Drivers of Adherence in Obesity Highlight the Need for Patient-Centered Interventions | Andrea Leith |  Received | 
|  | |||
| 207-HPR | The Intercept of Real-World Evidence (RWE) Health Equity and Health Technology Assessment (HTA): A Structured Literature Review of Health Policy and Methodological Guidance | Tracey Tingle |  Received | 
|  | |||
| 208-MSR | Uncovering Patient Narratives of Opioid Use and Recovery Using Large Language Models for Topic and Emotion Analysis of Social Media Discussions | Ashwin Rai |  Received | 
|  | |||
| 211-EPH | SEPTAL MYECTOMY FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS IN THE BRAZILIAN PUBLIC HEALTH SYSTEM a Real-World STUDY | Ana Paula Casagrande Drozda Oliveira |  Received | 
|  | |||
| 213-MSR | Use of Multi-Level Network Meta Regression (ML-NMR) Model in RET Mutationpositive Medullary Thyroid Cancer (MTC) | Min-Hua Jen |  Received | 
|  | |||
| 213-CO | Review of Index Line Selection Methods in Hemato-oncology Externally Controlled Trials: A Secondary Analysis of the Hermans Et Al Systematic Review | Michael Wallington |  Received | 
|  | |||
| 214-HPR | The Role of Technological Innovation and Policy in the Evolution of Care Models in Italy | FRANCESCA MARIANI |  Received | 
|  | |||
| 216-CO | Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-negative Breast Cancer (TNBC): Systematic Literature Review (SLR) | Patricia Dorling |  Received | 
|  | |||
| 217-MSR | Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-term Treatment Effect: An Example in Alzheimer´s Disease | Marie-Ange Paget |  Received | 
|  | |||
| 218-CO | Semaglutide Weight Outcomes Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Real-World Setting | Yestle Kim |  Received | 
|  | |||
| 218-HPR | Through a Glass Darkly: The What, How, and What Now for Global Net Price Transparency | David Carr |  Received | 
|  | |||
| 220-EE | Cost-Effectiveness Analysis of Sparsentan for the Treatment of Immunoglobulin a Nephropathy in Spain | Antonio Ramirez de Arellano |  Received | 
|  | |||
| 222-HPR | Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-offs | Jaime Espin |  Received | 
|  | |||
| 223-CO | Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study | Fang Zhou |  Received | 
|  | |||
| 225-PCR | The Burden of Cognitive Impairment Associated With Schizophrenia (CIAS) on People With Lived Experience (PWLE): A National Canadian Survey | Raymond Milan |  Received | 
|  | |||
| 227-HPR | Understanding Reimbursement and Access Policies for Immunoglobulins and other Plasma-Derived Medicinal Products Across Europe | Marek Kortus |  Received | 
|  | |||
| 227-HTA | Mapping Writer-AI Conversations for HTA: An Analysis of 12500 Messages | Anton Orell Wiehe |  Received | 
|  | |||
| 229-HTA | Maximizing Acceptance of Patient-Reported Outcome Data in German HTA Decision Making: Results From a Horizon Scan | Kristi Bertzos |  Received | 
|  | |||
| 230-EE | Cost-Effectiveness Evaluation of RSVpreF Vaccine for Preventing RSV Among Older Adults With High Risk Under Taiwan National Vaccination Program | Sheng-Tzu Hung |  Received | 
|  | |||
| 233-HTA | Middle East NICE Move Towards Standardized Health Technology Assessment | Dominika Meszarosova |  Received | 
|  | |||
| 237-EE | Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Stabilised Prefusion F Subunit Vaccine (RSVpreF) Among Older Adults in Ireland | Mary MacKinnon |  Received | 
|  | |||
| 238-EE | Cost-Effectiveness of CKD Screening: Insights for the 60+ General Population and Those With Type 2 Diabetes | George Bungey |  Received | 
|  | |||
| 239-CO | The Effect of Nutritional Supplements on Semen Quality and Pregnancy Rates in Patients With Male Factor Infertility: A Systematic Literature Review and Network Meta-Analysis | Lauren Rengger |  Received | 
|  | |||
| 240-HPR | Who Pays the Price? International Impacts of US Drug Cost Benchmarking | Ariel Hammerman |  Received | 
|  | |||
| 242-PCR | The Road Ahead: A Qualitative Study Mapping the Experience of Patients With Chronic Kidney Disease | Lillian Witting |  Received | 
|  | |||
| 242-HTA | Navigating Evidence Requirements for Joint Clinical Assessment (JCA): Practical Considerations for Systematic Literature Review (SLR) and Indirect Treatment Comparisons (ITC) | Caroline von Wilamowitz-Moellendorff |  Received | 
|  | |||
| 244-CO | The Incidence and Economic Impact of Major Adverse Events Associated with Intravascular Temperature Management: A Systematic Review, Analysis, and Model | Timothy Kelly |  Received | 
|  | |||
| 244-HTA | Navigating HTA Requirements: The Current Landscape of Alzheimers Disease Modifying Treatments | Nathalie Abi-Saleh |  Received | 
|  | |||
| 246-CO | The Prevalence of COAs and DHTs for Studying Sleep Disorders in Clinical Trials | Deepika Sehijpaul |  Received | 
|  | |||
| 249-HTA | Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond | Lauren Rengger |  Received | 
|  | |||
| 254-HTA | NICE Has Embraced Single-Arm Trials in Technology Appraisals but Where Is the Guidance? | Charlotte Mitchell |  Received | 
|  | |||
| 255-CO | Treatments for Children With Newly Diagnosed Medulloblastoma-A Systematic Review Of Randomized Controlled Trials | Lauren Rengger |  Received | 
|  | |||
| 256-EE | Cost-Effectiveness of Implementing Spirometry Screening for COPD in Primary Care in Russia | Nuriya Musina |  Received | 
|  | |||
| 256-CO | UDCA Treatment Response in Primary Biliary Cholangitis in the United States | Diane Ito |  Received | 
|  | |||
| 257-CO | Understanding Xlh´s Impact: Incorporating Patient Perspectives to Develop a Comprehensive Conceptual Disease Model CDM to Drive Patient Engagement and the Generation of Meaningful Patient Experience Data | Laura Meade |  Received | 
|  | |||
| 258-EPH | Treatment Patterns in Epithelial Ovarian Cancer (EOC) With a Focus on Recurrent EOC and PARPi Progressors: A Targeted Literature Review Across Selected Countries | Aurore BERGAMASCO |  Received | 
|  | |||
| 258-HTA | Nutrieconomics: Concept and Expert Consensus on Health Technology Assessment of Nutritional Interventions in Brazil | Erica Camargo |  Received | 
|  | |||
| 260-CO | Using Natural Language Processing to Identify Sequencing Patterns in Advanced Urothelial Carcinoma : A Real-World Observational Study | Thibaut Vergnol |  Received | 
|  | |||
| 260-EE | Cost-Effectiveness of Mixed Maternal RSVpreF/Infant Nirsevimab Immunization Approach Versus Nirsevimab Alone for the Prevention of Respiratory Syncytial Virus in Chile | Mary MacKinnon |  Received | 
|  | |||
| 260-PCR | Utility Estimates for Healthstates Associated With Immune Thrombocytopenia: A Systematic Literature Review | Isabelle Lundqvist |  Received | 
|  | |||
| 261-EE | Cost-Effectiveness of Mixedapproach Maternal RSVpreF/Infant Nirsevimab Immunization Versus Nirsevimab Alone for Prevention of Respiratory Syncytial Virus in Spain | Mary MacKinnon |  Received | 
|  | |||
| 266-PCR | We Hear What You Are Saying: The Design and Development of the Qualitative Interview Feedback Survey (QIFS) for Use in Qualitative Patient-Centred Outcomes Research Studies | Gemma Al-Jassar |  Received | 
|  | |||
| 269-PCR | Why Are Patient-reported Outcome Measure (PROM) Results Missing from Labels of Obesity Management Medications? | Ana Liberato |  Received | 
|  | |||
| 271-HTA | Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis | Shivani Shah |  Received | 
|  | |||
| 277-EE | Cost-Effectiveness of Strategies to Prevent Respiratory Syncytial Virus Infections Among Infants in Ireland | Mary MacKinnon |  Received | 
|  | |||
| 277-EPH | Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset | Jing Zhao |  Received | 
|  | |||
| 279-HTA | Reassessing NICE´s Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework | Lauren Rengger |  Received | 
|  | |||
| 279-EPH | Years of Life Lost and Productivity Costs Due to Premature Cancerrelated Mortality in Ukraine and in Kiev City, Lviv and Cherkassy Regions | Bernadette Pöllinger |  Received | 
|  | |||
| 280-EPH | Years of Life Lost and Productivity TB1 SY2 Costs Due to Premature Cancer-Related Mortality in Morocco | Bernadette Pöllinger |  Received | 
|  | |||
| 286-EE | Costs and Healthcare Resource Utilization Associated With Generalised Myasthenia Gravis: A Systematic Literature Review | Nicholas Adlard |  Received | 
|  | |||
| 290-EE | Costs Associated With the Treatment of Surgical Site Infections in Solid Organ Transplant Recipients: A Scoping Review | Ramon Oliveira |  Received | 
|  | |||
| 304-HTA | Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions | Nate Smith |  Received | 
|  | |||
| 314-HTA | The Development of the Multi Criteria Decision Analysis in Specialized Burn Care: The Methodological Process | Raaba S.M. Thambithurai |  Received | 
|  | |||
| 316-EE | Danicopan a Dominant Option for the Treatment of Patients With Paroxysmal Nocturnal Haemoglobinuria PNH With Residual Haemolytic Anaemia in Spain | Sandra Merino-Montero |  Received | 
|  | |||
| 319-EE | Decluttering Complexity: A Pragmatic Framework for Simplifying Global Health Economic Models for HTA | Patricia Homar |  Received | 
|  | |||
| 320-HTA | The Impact of Using England Real-World Evidence to Establish the NICE Severity Modifier in Metastatic Urothelial Carcinoma mUC | Will Perkin |  Received | 
|  | |||
| 321-HTA | The Interim Acceptance and Ultra-Orphan Pathways in Scotland: An Update | Ethan Prince |  Received | 
|  | |||
| 322-HTA | The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries | Vania Cristina Canuto Santos |  Received | 
|  | |||
| 323-HTA | The Landscape of the Use of Artificial Intelligence and Machine Learning AIMI Methods in Health Technology Assessment HTA Submissions | Ins Guerra |  Received | 
|  | |||
| 326-EE | Development and Validation of a Novel Patient Microsimulation Cost-Effectiveness Model to Evaluate Automated Insulin Delivery Systems in Type 2 Diabetes | Joshua Weinstein |  Received | 
|  | |||
| 326-HTA | The Phantom Menace: How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access | Bersabhe Solomon |  Received | 
|  | |||
| 328-HTA | The Rise of Optimisation in NICE Guidance: A Two-Decade Review With a Focus on Prevention | Rachel Barr-Keenan |  Received | 
|  | |||
| 341-EE | Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US | Jaehong Kim |  Received | 
|  | |||
| 344-EE | Drivers of Inpatient Costs in Oncology Patients Undergoing Major Abdominal Surgery: Evidence from a Middle-Income Country | Jorge Alexis Medina Parra |  Received | 
|  | |||
| 349-EE | Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China | Yanan Sheng |  Received | 
|  | |||
| 350-EE | Economic and Clinical Impact of Older Adult Vaccination with The Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico | Rengina Kefalogianni |  Received | 
|  | |||
| 353-EE | Economic Burden and Health Related Quality of Life Associated With Schizophrenia in Saudi Arabia | Ahmed Alghamdi |  Received | 
|  | |||
| 356-HTA | Viable Reimbursement and Financing Models for mHealth Interventions in Sub-Saharan Africa: A Narrative Review | Gareth Obery |  Received | 
|  | |||
| 362-HTA | What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques | Emily Morton-West |  Received | 
|  | |||
| 368-HTA | When Less Is More? Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-level Evidence | Andrea Berardi |  Received | 
|  | |||
| 379-EE | Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil | Fabian Schmidt |  Received | 
|  | |||
| 390-EE | Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management | Bjoern Schwander |  Received | 
|  | |||
| 391-EE | Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups | Colleen Dumont |  Received | 
|  | |||
| 412-EE | Enhancing Palliative Care in Intensive Care Units (EPIC) Trial Design of the Health Economic Sub-study | Michaela Barbier |  Received | 
|  | |||
| 419-EE | Estimating Health Utility Decrements Associated With Chronic Disease Outcomes Using MEPS | Piaopiao Li |  Received | 
|  | |||
| 427-EE | Economic burden of chikungunya in an outbreak setting: A modelling study in Rome and Nice | Adrianne de Roo |  Received | 
|  | |||
| 457-EE | Exploring LLMs in the Conceptual and Functional Construction of Health Economic Models: A Case Study on Alzheimers Diagnostic Cost-Effectiveness Model | Viviana Hernandez |  Received | 
|  | |||
| 478-EE | Foregone Net Monetary Benefit From Underdiagnosis and Undertreatment of Mild Cognitive Impairment Due to Alzheimer´s Disease in the Medicare Population | Scott Johnson |  Received | 
|  | |||
| 483-EE | Has the IRA Impacted International Price Differentials? Comparing US and German Drug Prices in the Era of MFP | Loukia Mantzali |  Received | 
|  | |||
| 502-EE | Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis | Tomohiro Kondo |  Received | 
|  | |||
| 517-EE | Healthcare Resource Utilization for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan | Jade Garratt-Wheeldon |  Received | 
|  | |||
| 519-EE | Hereditary Transthyretin Amyloidosis (ATTRv) Below the Age of 70 Healthcare Resource Utilization and Mortality | Klas Rikner |  Received | 
|  | |||
| 540-EE | Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain | Antonio Ramirez de Arellano |  Received | 
|  | |||
| 553-EE | Informing the Sustainable Development of Novel Therapies Using Value-Based Real Options Analysis | Deirdre Weymann |  Received | 
|  | |||
| 576-EE | Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment | Marta Medaglia |  Received | 
|  | |||
| 580-EE | Microsimulation Model to Estimate the Clinical and Cost Burden of Adverse Events Related to Long-Term Oral Corticosteroid Usage in Autoimmune Diseases in the United States | Rachel Meade |  Received | 
|  | |||
| 583-EE | Model Structure Variability in NICE HTAs: Evidence From Asthma and TMA Appraisals to Support the Need for Disease-Specific Reference Models | Patricia Homar |  Received | 
|  | |||
| 589-EE | Modelling the Healthcare Burden of Oral Corticosteroid Use in Mexico | Zahava Gabriel |  Received | 
|  | |||
| 590-EE | Modelling Treatmentfree Remission Outcomes for Asciminib in Newly Diagnosed Chronic Myeloid Leukaemia: Assumptions Methodology and Projections | Shaun Walsh |  Received | 
|  | |||
| 595-EE | Obstructive Sleep Apnea (OSA) Phenotypes and the Personalized Impact of Positive Airway Pressure (PAP) Therapy on Healthcare Resource Use | MELIKE DEGER WEHR |  Received | 
|  | |||
| 599-EE | Optimization of the EVAR Pathway: An Integrated Organizational Model for Clinical Efficiency and Economic Sustainability | Elisa Tacconi |  Received | 
|  | |||
| 606-EE | Patient Blood Management With Intravenous Iron Is Economically Advantageous Compared to Usual Care in German Hospitals | Mathias Flume |  Received | 
|  | |||
| 613-EE | Preliminary Observational Analysis of Digital Health Platform Associated With Medical Cost Changes in Employer Population | Yifat Fundoiano-Hershcovitz |  Received | 
|  | |||
| 615-EE | Price Behavior of Originator Adalimumab After Biosimilars Entry: Evidence From the Colombian Market | carolina arias |  Received | 
|  | |||
| 641-EE | Reducing External Plasma Dependency: Impact for the Portuguese National Health Service | Joana Alves |  Received | 
|  | |||
| 649-EE | Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches | Richard Mee |  Received | 
|  | |||
| 652-EE | Review of CEESP ICERs for Orphan and Nonorphan Treatments in France, 2024-2025 | Kate Monk |  Received | 
|  | |||
| 656-EE | Site of Care Cost-Effectiveness of Axicabtagene Ciloleucel in Relapsed/Refractory Second-Line or Later Large B-cell Lymphoma in the United States: Analyses for Inpatient and Outpatient Infusion Settings | Nate Smith |  Received | 
|  | |||
| 662-EE | Societal Burden of Specific Learning Disorders With Focus on Secondary Mental Health Problems in Japan | Tomoyasu Muto |  Received | 
|  | |||
| 684-EE | Technical Validation of Health Economic Models: Is There a Gold Standard? Assessment and Refinement of Current Checklist Tools | Viviana Hernandez |  Received | 
|  | |||
| 686-EE | THE BROADER ECONOMICS OF CHRONIC SPONTANEOUS URTICARIA CSU IN JAPAN: ASSESSING SOCIETAL AND FISCAL BENEFITS OF NOVEL THERAPIES | Nikos Kotsopoulos |  Received | 
|  | |||
| 687-EE | The Budget Impact and Time Savings of Introducing Subcutaneously-Administered Nivolumab and Hyaluronidase (NIVO SC) to Patients Receiving Intravenouslyadministered Nivolumab (NIVO IV) Across Indications in Canada | Tomaras Dimitrios |  Received | 
|  | |||
| 693-EE | The Cost-Effectiveness of Imlifidase Idefirix® for Desensitisation Treatment of Highly Sensitised Adult Kidney Transplant Patients in Ireland | Kate Monkn |  Received | 
|  | |||
| 705-EE | The Economic Impact of Time-to-Target-Temperature of Different Surface Cooling Technologies for Temperature Management in Critically Ill Patients: A Systematic Review, Analysis, and Model | Timothy Kelly |  Received | 
|  | |||
| 714-EE | The Impact of Inflation: A Cost Analysis in the Spanish Pharmaceutical Sector From 2014 to 2023 | Teresa Dominguez |  Received | 
|  | |||
| 733-EE | Transfusion-related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective | Dipika Morgan |  Received | 
|  | |||
| 734-EE | Treatment Failure Event Categories Reveal Progressive Increases in Disease and Economic Burden Among Patients With Major Depressive Disorder | Ling Zhang |  Received | 
|  | |||
| 736-EE | Treatment Patterns and Healthcare Resource Utilization in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in England: A Retrospective, Observational Cohort Study | Amanda Pulfer |  Received | 
|  | |||
| 760-EE | DMD in Germany: A Societal Cost Analysis | Tobias Hackmann |  Received | 
|  | |||


 
 
									
				9 - 12 November Glasgow

 ACTIVE FROM 17/11/2042 TO 17/11/2042
     ACTIVE FROM 17/11/2042 TO 17/11/2042
				|  | Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world.  To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.   |  | ||
|  | ||||
|  | 

